Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cat scratch cure? injection may shrink swollen nodes faster

NCT ID NCT03132116

Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether injecting the antibiotic gentamicin directly into swollen lymph nodes helps people with cat scratch disease recover faster. 75 participants received either the injection or a placebo, along with standard oral antibiotics. The goal was to see if the injection reduced node size and avoided the need for drainage or surgery within 28 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

75 people

The number who actually took part.

Started

May 2017

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent * Suppurated CSD's adenitis: * Suppurated form of adenitis confirmed by echography * Serology positive for Immunoglobulin G and/or Immunoglobulin M against B. henselae Exclusion Criteria: * Suppurated adenitis non related to CSD * Non-suppurated CSD's adenitis * Suppurated CSD's adenitis already fistulized * Suspected visceral B. henselae infection (neurologic or ophthalmic symptoms, hepato-splenic or valvular involvement confirmed by echography) * Immunodepression (except diabetes) * Pregnancy * Contraindication to pus aspiration from lymphadenitis (history of bleeding or patient taking curative anticoagulation therapy or platelet count \< 50.000/mm3) * Contraindication to azithromycin (history of QT interval prolongation, history of liver toxicity of hypersensitivity to macrolides or treatment with ergotamine, dihydroergotamine, bepridil, cisapride, pimozide, mizolastine or colchicine) or to aminoglycosides (myasthenia, history of hypersensitivity to aminoglycosides).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cat-scratch disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cat-scratch disease infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cat-scratch disease

Contacts and locations

Locations

  • Albi Hospital

    Albi, France

  • Amiens-Picardie Hospital

    Amiens, France

  • Angers Hospital

    Angers, France

  • Auch Hospital

    Auch, France

  • Bordeaux University Hospital

    Bordeaux, France

  • Cahors Hospital

    Cahors, France

  • Castres Hospital

    Castres, France

  • Hospices Civils Lyon

    Lyon, France

  • Limoges University Hospital

    Limoges, France

  • Microbiology Laboratory

    Toulouse, 31059, France

  • Montauban Hospital

    Montauban, France

  • Montpellier University Hospital

    Montpellier, France

  • Nîmes University Hospital

    Nîmes, France

  • Pau Hospital

    Pau, France

  • Perpignan Hospital

    Perpignan, France

  • Rennes Hospital

    Rennes, France

  • Rodez Hospital

    Rodez, France

  • Saint-Brieuc Hospital

    Saint-Brieuc, France

  • Saint-Nazaire Hospital

    Saint-Nazaire, France

  • Tarbes Hospital

    Tarbes, France

  • Vendée Hospital

    La Roche-sur-Yon, France